ISR Immune System Regulation Holding (ISR.ST) Stock Analysis & AI Equity Report

Biotechnology SEK Explore free reports
Generate fresh report — €50.00

ISR Immune System Regulation Holding (ISR.ST) overview

ISR Immune System Regulation Holding (ISR.ST) stock analysis and AI equity research. For the latest completed financial year, 2021, ISR Immune System Regulation Holding reported revenue of SEK 0m and operating profit of SEK -78.6m; the year-end share price was 9.20 SEK and market capitalisation was SEK 635m. ISR Immune System Regulation Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ISR Immune System Regulation Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 38.5mFY 2021
Share price9.20 SEKFY 2021 year end
RevenueSEK 0mFY 2021
Operating profitSEK -78.6mFY 2021
Net earningsSEK -78.6mFY 2021
Market capitalisationSEK 635mFY 2021 year end

Figures updated on 2025-09-04. Data will be refreshed during report generation.

About ISR Immune System Regulation Holding

ISR Immune System Regulation Holding AB is a Swedish biotechnology company focused on immunotherapy drug development. It develops immunostimulatory products and vaccine candidates intended to harness the immune system against viral and infectious diseases, including HIV and hepatitis B, as well as cancer. The company is based in Solna and listed on Nasdaq First North Growth Market.

Generate the ISR Immune System Regulation Holding report

ISR Immune System Regulation Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ISR Immune System Regulation Holding and represent the latest completed financial year (2021). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.